Acarbose ameliorates spontaneous type2 diabetes in db/db mice by inhibiting PDX1 methylation

Diyi Zhou1, Lijun Chen1, Xin Mou1

  • 1Department of Endocrinology, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang 310000, P.R. China.

Molecular Medicine Reports
|November 25, 2020
PubMed

Insights

Acarbose treatment in diabetic mice reduced PDX-1 methylation and improved islet beta-cell function. This suggests acarbose may offer a novel therapeutic strategy for type-2 diabetes mellitus.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Type-2 diabetes mellitus (T2DM) involves insulin resistance and impaired islet beta-cell function.
  • PDX-1 gene methylation is implicated in T2DM development.
  • Acarbose, an alpha-glucosidase inhibitor, delays glucose absorption.

Purpose of the Study:

  • To investigate the effect of acarbose on PDX-1 methylation in islet beta-cells of diabetic db/db mice.
  • To assess acarbose's impact on glucose and lipid metabolism and pancreatic changes in T2DM mice.

Main Methods:

  • Assessment of metabolic parameters (body weight, HbA1c, glucagon, lipids, FBG) and glucose/insulin tolerance tests.
  • Immunohistochemistry for pancreatic pathology, BrdU assay for cell proliferation.
  • Methylation-specific PCR and Western blot to evaluate PDX-1 methylation and expression.

Main Results:

  • Acarbose treatment decreased HbA1c, glucagon, and fasting blood glucose levels in diabetic mice.
  • Acarbose promoted islet beta-cell proliferation and downregulated PDX-1 methylation and cytoplasmic expression.
  • While body weight increased, overall metabolic control and beta-cell function markers improved.

Conclusions:

  • Acarbose inhibits PDX-1 methylation in islet beta-cells of diabetic mice.
  • Acarbose promotes islet beta-cell proliferation, suggesting a potential therapeutic role in T2DM.
  • These findings highlight acarbose as a potential new strategy for managing type-2 diabetes mellitus.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
415
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
391
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
479